Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses
Delia Goletti, Linda Petrone, Davide Manissero, et al.
Clinical Microbiology and Infection (2021) Vol. 27, Iss. 12, pp. 1784-1789
Open Access | Times Cited: 59

Showing 26-50 of 59 citing articles:

Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response
Areti Tychala, Georgios Meletis, Eugenia Katsimpourlia, et al.
Human Vaccines & Immunotherapeutics (2021) Vol. 17, Iss. 12, pp. 5148-5149
Open Access | Times Cited: 18
Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy
Tonino Alonzi, Alessandra Aiello, Linda Petrone, et al.
Cells (2021) Vol. 11, Iss. 1, pp. 52-52
Open Access | Times Cited: 16
Exosomal Vaccine Loading T Cell Epitope Peptides of SARS-CoV-2 Induces Robust CD8+ T Cell Response in HLA-A Transgenic Mice
Anran Shen, Xiaoxiao Jin, Tao‐Tao Tang, et al.
International Journal of Nanomedicine (2022) Vol. Volume 17, pp. 3325-3341
Open Access | Times Cited: 11
Kinetics of cellular and humoral immunogenicity and effectiveness of SARS‐CoV‐2 booster vaccination in hematologic neoplasms
Moraima Jiménez, Candela Fernández‐Naval, Vı́ctor Navarro, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 8, pp. 1204-1213
Closed Access | Times Cited: 6
Spike protein is a key target for stronger and more persistent T-cell responses—a study of mild and asymptomatic SARS-CoV-2 infection
Ivan Ssali, Susan Mugaba, Arthur Kalyebi Watelo, et al.
International Journal of Infectious Diseases (2023) Vol. 136, pp. 49-56
Open Access | Times Cited: 5
SARS-CoV-2 antibody persistence after five and twelve months: A cohort study from South-Eastern Norway
Marjut Sarjomaa, Lien My Diep, Chi Zhang, et al.
PLoS ONE (2022) Vol. 17, Iss. 8, pp. e0264667-e0264667
Open Access | Times Cited: 9
Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy
Saeid Najafi Fard, Elisa Petruccioli, Chiara Farroni, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 9
Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of basic immunity show similar immunogenicity regarding long-term spike-specific cellular immunity in healthcare workers
Isabell Wagenhäuser, Giovanni Almanzar, Franziska Bernhardine Förg, et al.
Vaccine (2024) Vol. 42, Iss. 21, pp. 126132-126132
Open Access | Times Cited: 1
Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4+ T-Cell Responses
Emelie Marklund, Susannah Leach, Kristina Nyström, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 12
Long Covid, Short Magnesium
Patrick Chambers
OALib (2022) Vol. 09, Iss. 05, pp. 1-25
Open Access | Times Cited: 8
Humoral and cell-mediated immune responses to BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis
Gianfranco Alicandro, B.S. Orena, Chiara Rosazza, et al.
Vaccine (2023) Vol. 41, Iss. 28, pp. 4114-4120
Open Access | Times Cited: 4
Accuracy of interferon gamma release assays for the COVID-19 immunity assessment
Francis Stieber, Nadia Allen, Kara Carpenter, et al.
Journal of Virological Methods (2022) Vol. 302, pp. 114472-114472
Open Access | Times Cited: 7
Computer-Based Immunoinformatic Analysis to Predict Candidate T-Cell Epitopes for SARS-CoV-2 Vaccine Design
Xueyin Mei, Pan Gu, Chuanlai Shen, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 7
An adjusted ELISpot-based immunoassay for evaluation of SARS-CoV-2-specific T-cell responses
Hao Lin, Jie Zhang, Shaobo Dong, et al.
Biosafety and Health (2022) Vol. 4, Iss. 3, pp. 179-185
Open Access | Times Cited: 6
Cellular immunity reflects the persistent symptoms among COVID-19 recovered patients in Japan
Yoshiharu Miyata, Kohjin Suzuki, Tatsuya Nagano, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 3
The impact of hybrid immunity on immune responses after SARS‐CoV‐2 vaccination in persons with multiple sclerosis treated with disease‐modifying therapies
Monika Rabenstein, Olivia G. Thomas, Giorgia Carlin, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 12, pp. 3789-3798
Open Access | Times Cited: 3
Neuropeptide Calcitonin Gene-Related Peptide Promotes Immune Homeostasis of Bacterial Meningitis by Inducing Major Histocompatibility Complex Class II Ubiquitination
Yuxiang Li, Lanying Wang, Zhenfang Gao, et al.
The Journal of Infectious Diseases (2023) Vol. 229, Iss. 3, pp. 855-865
Closed Access | Times Cited: 3
Rheumatoid arthritis and older age are associated with lower humoral and cellular immune response to primary series COVID-19 mRNA vaccine
Holly Dudley, Megan L. O’Mara, Ann Auma, et al.
Vaccine (2023) Vol. 41, Iss. 41, pp. 6112-6119
Open Access | Times Cited: 3
Prolonged SARS-CoV-2 Infection in Patients Receiving Anti-CD20 Monoclonal Antibodies: A Diagnostic Challenged by Negative Nasopharyngeal RT-PCR and Successful Treatment with COVID-19 High-Titer Convalescent Plasma
Léa Da Silva, Timothée Klopfenstein, Vincent Gendrin, et al.
Viruses (2023) Vol. 15, Iss. 11, pp. 2220-2220
Open Access | Times Cited: 3
Assessing T-Cell Immunity in Kidney Transplant Recipients with Absent Antibody Production after a 3rd Dose of the mRNA-1273 Vaccine
María Infantino, Aris Tsalouchos, Edda Russo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12333-12333
Open Access | Times Cited: 5
Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort study
Michaela Koehm, Maximilian Klippstein, Stephanie Dauth, et al.
RMD Open (2023) Vol. 9, Iss. 3, pp. e003094-e003094
Open Access | Times Cited: 2
SARS‐CoV‐2 (COVID‐19)‐specific T cell and B cell responses in convalescent rheumatoid arthritis: Monozygotic twins pair case observation
Lucas C. M. Arruda, Ahmed Gaballa, Rui Da Silva Rodrigues, et al.
Scandinavian Journal of Immunology (2022) Vol. 95, Iss. 5
Open Access | Times Cited: 4
Critical role of diagnostic SARS-CoV-2 T cell assays for immunodeficient patients
Rohan Ameratunga, See‐Tarn Woon, Richard Steele, et al.
Journal of Clinical Pathology (2022) Vol. 75, Iss. 12, pp. 793-797
Closed Access | Times Cited: 4
Initial antigen encounter determines robust T-cell immunity against SARS-CoV-2 BA.2.86 variant three years later
Rocío Rubio, Alexei Yavlinsky, Marina Escalera Zamudio, et al.
Journal of Infection (2024), pp. 106402-106402
Open Access
Immunogenicity and Tolerance of BNT162b2 mRNA Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Patients
Ahmed Amine Ben Khlil, Imen Zamali, Dorra Belloumi, et al.
Vaccines (2024) Vol. 12, Iss. 2, pp. 174-174
Open Access

Scroll to top